Fig. 8.

NLRP3 inhibitor abolishes the detrimental effects of rLCN2 on pyroptosis and functional prognosis. a, b WB analysis of LCN2, 24p3R and target protein in the NLRP3 inflammasome and pyroptosis pathway. n = 5 per group; ***P < 0.001, **P < 0.01, *P < 0.05 vs. sham-operated group; ^###P < 0.001; ^$$$P < 0.001, ^$$P < 0.01; ^&&&P < 0.001. c, d Detection of MCC950 function by WB analysis of NLRP3 expression. n = 3 per group; ***P < 0.001, **P < 0.01, *P < 0.05 vs. sham-operated group; ^###P < 0.001. e Neurological impairment assessment 24 h after MCAO. n = 8 per group; ^#P < 0.05; ^$$P < 0.01; ^&&&P < 0.001. Data are mean ± SD